Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Likun Li(The University of Texas MD Anderson Cancer Center), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center), Carlo Toniatti(The University of Texas MD Anderson Cancer Center), Spyridon P. Basourakos(Mayo Clinic in Arizona), Ana M. Aparicio(The University of Texas MD Anderson Cancer Center), Jeri Kim(The University of Texas MD Anderson Cancer Center), Dimitrios Korentzelos(University of Pittsburgh Medical Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Jianhua Yin(BGI Group (China)), Theodoros Karantanos(Johns Hopkins University), Paul G. Corn(Cornell University), Timothy P. Heffernan(The University of Texas MD Anderson Cancer Center), Ju‐Seog Lee(The University of Texas MD Anderson Cancer Center), Wenjun Chang(Second Military Medical University), Guang Yang(Jinan University), Hyun‐Sung Lee(Baylor College of Medicine), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Styliani Karanika(Johns Hopkins University), Yong Luo(Capital Medical University), Sanghee Park(Hanbat National University), Abul Kalam Azad(The University of Texas MD Anderson Cancer Center), Xuemei Zuo(The University of Texas MD Anderson Cancer Center), Wenhui Wu(The University of Texas MD Anderson Cancer Center), Jian H. Song(The University of Texas MD Anderson Cancer Center), Gary E. Gallick(The University of Texas MD Anderson Cancer Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Jiangxiang Wang(The University of Texas MD Anderson Cancer Center), Bradley M. Broom(The University of Texas MD Anderson Cancer Center)
Cited by 307
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k